New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on December 1, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Bruce Cozadd has made a significant move by selling 77,500 shares of Jazz Pharmaceuticals stock, with the transaction valued at an impressive $13,780,128.
Recent Updates on JAZZ stock
Jazz Pharmaceuticals has experienced significant developments in the past 24 hours, primarily driven by positive Phase 3 trial results for their drug Ziihera, which is being evaluated for treating gastric cancer. UBS downgraded Jazz to Neutral, citing that the recent 25% stock increase reflects the current valuation and balanced risk/reward profile, with no major catalysts on the horizon. In contrast, Truist, Baird, BofA, and Wells Fargo raised their price targets, emphasizing the strong potential of Ziihera as a pipeline-in-a-drug, capable of achieving substantial peak sales in both the U.S. and global markets. The promising trial outcomes have positioned Ziihera as a potential new standard of care in gastroesophageal adenocarcinoma, with further implications for other cancer indications, thus boosting the stock’s outlook.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall stock score is driven by strong earnings call performance and positive technical indicators, despite challenges in financial performance and valuation. The company’s strategic advancements and record revenues are significant positives, but profitability issues and potential future competition pose risks.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 42.64%
Average Trading Volume: 949,512
Technical Sentiment Signal: Buy
Current Market Cap: $10.73B